BioPorto A/S (CPH:BIOPOR)
Denmark · Delayed Price · Currency is DKK | Market Cap | 561.44M |
| Revenue (ttm) | 36.56M |
| Net Income (ttm) | -86.80M |
| Shares Out | 495.10M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,731 |
| Average Volume | 388,066 |
| Open | 1.110 |
| Previous Close | 1.152 |
| Day's Range | 1.104 - 1.168 |
| 52-Week Range | 1.000 - 1.878 |
| Beta | 1.31 |
| RSI | 49.40 |
| Earnings Date | Nov 19, 2025 |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acu... [Read more]
Financial Performance
In 2024, BioPorto's revenue was 36.24 million, an increase of 17.07% compared to the previous year's 30.96 million. Losses were -68.24 million, 21.2% more than in 2023.
Financial StatementsNews
BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes
24 November 2025 Announcement no. 27 BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number o...
BioPorto A/S 2025 Q3 - Results - Earnings Call Presentation
Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S
13 November 2025 Announcement no. 25 Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximat...
BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement
13 November 2025 Announcement no. 24 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOU...
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today pre-announced the key financial results for the third quarter of 2025 and revis...
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
September 26, 2025 News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“...
BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.
August 15, 2025 Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.
BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.
August 15, 2025 Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. Copenhagen, De...
BioPorto A/S to host an investor webcast on the results for the first half of 2025
July 29, 2025 News release BioPorto A/S to host an investor webcast on the results for the first half of 2025 COPENHAGEN, DENMARK, July 29, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Compan...
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
July 28, 2025 News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicin...
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025 Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIR...
BioPorto A/S to host first quarter 2025 earnings webcast for investors
April 28, 2025 News release BioPorto A/S to host first quarter 2025 earnings webcast for investors COPENHAGEN, DENMARK, April 28, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BI...
BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million
News Release April 25, 2025 BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) ...
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes
April 25, 2025 Announcement no. 12 BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and v...
Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
April 15, 2025 Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 mil...
Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
April 15, 2025 Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 mil...
BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.
April 14, 2025 Announcement no. 10 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH...
Notice convening the Annual General Meeting in BioPorto A/S
20 March 2025 Announcement no. 7 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Compa...
BioPorto announces the Annual Report for 2024
March 20, 2025 Announcement no. 06 ...
BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029
March 19, 2025 Announcement no. 05 BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 C...
BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates
March 4, 2025 Announcement no. 04 BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates COPENHAGE...
Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations
February 27, 2025 Announcement no. 03 Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations COPENHAGEN, DENMARK, February ...
BioPorto A/S appoints new interim Chairman of the Board
January 29, 2025 Announcement no. 02 BioPorto A/S appoints new interim Chairman of the Board COPENHAGEN, DENMARK, January 29, 2025, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no.
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – Bi...
BioPorto commences process to appoint new Chair of the Board of Directors
December 16, 2024 Announcement no. 23 BioPorto commences process to appoint new Chair of the Board of Directors COPENHAGEN, DENMARK, December 16, 2024 (GLOBE NEWSWIRE) – The Board of Directors of Bio...